Geraldine Engels

Geraldine Engels

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 May 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
MFMats Ingmar Fortmann
Mats Ingmar Fortmann
MDMarie-Theres Dammann
Marie-Theres Dammann
AHAlexander Humberg
Alexander Humberg
BSBastian Siller
Bastian Siller
GSGuido Stichtenoth
Guido Stichtenoth
OCon behalf of the German Neonatal Network (GNN) and the PRIMAL Consortium
on behalf of the German Neonatal Network (GNN) and the PRIMAL Consortium
This study is aimed at detecting the rate of untimely immunization in a large cohort of extremely low gestational age neonates (ELGANs) of the German Neonatal Network (GNN) and at addressing risk factors for delayed vaccination and associated long-term consequences. We performed an observational study of the GNN between 1st January 2010 and 31st December 2019. The immunization status for the hexavalent and pneumococcal immunization was evaluated in n = 8401 preterm infants <29 weeks of gestation. Univariate analysis and logistic/linear regression models were used to identify risk factors for vaccination delay and outcomes at a 5-year follow-up. In our cohort n = 824 (9.8%) ELGANs did not receive a timely first immunization with the hexavalent and pneumococcal vaccine. Risk factors for delayed vaccination were SGA status (18.1% vs. 13.5%; OR 1.3; 95% CI: 1.1–1.7), impaired growth and surrogates for complicated clinical courses (i.e., need for inotropes, necrotizing enterocolitis). At 5 years of age, timely immunized children had a lower risk of bronchitis (episodes within last year: 27.3% vs. 37.7%; OR 0.60, 95% CI: 0.42–0.86) but spirometry measures were unaffected. In conclusion, a significant proportion of ELGANs are untimely immunized, specifically those with increased vulnerability, even though they might particularly benefit from the immune-promoting effects of a timely vaccination.

6 October 2021 in Pediatric Transplantation
Verified
Journal Article
Open access
PDF file
GEGeraldine Engels
Geraldine Engels
BDBernd Döhler
Bernd Döhler
BTBurkhard Tönshoff
Burkhard Tönshoff
JOJun Oh
Jun Oh
AKAnne Kruchen
Anne Kruchen
CSCaner Süsal
Caner Süsal
Background: Approximately 1700 children per year with end‐stage kidney disease undergo kidney transplantation in Europe and the United States of America; 30%–50% are living donor kidney transplantations. There may be immunological differences between paternal and maternal donors due to transplacental exchange of cells between the mother and fetus during pregnancy leading to microchimerism. We investigated whether the outcome of living‐related kidney transplantation in young children is different after maternal compared with paternal organ donation.Methods: Using the international Collaborative Transplant Study (CTS) database, we analyzed epidemiological data of 7247 children and adolescents aged <18 years who had received a kidney transplant from either mother or father. Risk of treated rejection episodes and death‐censored graft failure were computed using the Kaplan‐Meier method and multivariable Cox regression.Results: In the recipient age group 1–4 years, the rate of treated rejection episodes in recipients of kidneys from maternal donors (N = 195) during the first 2 years post‐transplant was significantly lower (hazard ratio HR = 0.47, p = .004) than in patients receiving kidneys from paternal donors (N = 179). This association between donor sex and risk of treated rejections was not observed in children aged 5–9 years. The 5‐year death‐censored graft survival in children aged 1–4 years with a maternal or paternal donor was comparable.Conclusions: Maternal kidney donation in young pediatric renal transplant recipients is associated with an approximately 50% lower rate of treated rejection than paternal kidney donation. Whether this phenomenon is due to maternal microchimerism‐induced donor‐specific hyporesponsiveness must be evaluated in prospective mechanistic studies.

7 January 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
MDMarie-Theres Dammann
Marie-Theres Dammann
HKHannah Kraft
Hannah Kraft
GSGuido Stichtenoth
Guido Stichtenoth
KHKathrin Hanke
Kathrin Hanke
MZMichael Zemlin
Michael Zemlin
ONOn Behalf Of The German Neonatal Network
On Behalf Of The German Neonatal Network
Background: Very-low-birth-weight infants (VLBWIs; birth weight < 1500 g) are at an increased risk of complicated influenza infection, which frequently includes pneumonia, encephalitis or even death. Data on influenza immunization and its outcome in VLBWIs are scarce. This study aimed to provide epidemiological data on influenza immunization for German VLBWIs and hypothesized that immunization would protect VLBWIs from infection-mediated neurodevelopmental impairment and preserves lung function at early school age. Methods: In this observational population-based German Neonatal Network (GNN) study, infants born between 2009 and 2015 were invited to partake in a 6-year follow-up investigation including lung function and developmental testing. Uni- and multivariate analyses were performed to evaluate the clinical characteristics and outcomes of influenza-immunized VLBWIs compared to non-immunized VLBWIs. Results: Influenza immunization was performed in 871 out of the 3358 VLBWIs (26%) with six-year follow-up. Immunized infants were characterized by a low gestational age and higher rates of morbidity, particularly bronchopulmonary dysplasia. Although early immunization showed no safety signals and had protective effects on the long-term risk of bronchitis (OR: 0.2; CI: 0.1–0.6; p = 0.002), most VLBWIs (88.0%) were unimmunized in their first influenza season. Conclusions: Influenza immunization was not associated with improved lung function (forced expiratory volume in one second and forced vital capacity) or a better neurocognitive outcome (intelligence quotient and strengths and difficulties questionnaire) at early school age. In Germany, only one quarter of 6-year-old VLBWIs were immunized against influenza, particularly those born <28 gestational weeks and/or BPD. Specific influenza immunization guidelines that define evidence-based recommendations are needed for this vulnerable group.

21 December 2022 in Journal of Infection
Verified
Journal Article
Closed access
MKManuel Krone
Manuel Krone
IWIsabell Wagenhäuser
Isabell Wagenhäuser
KKKerstin Knies
Kerstin Knies
DHDaniela Hofmann
Daniela Hofmann
GEGeraldine Engels
Geraldine Engels
OAOliver Andres
Oliver Andres

24 March 2026 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
AHAndré Haufschild
André Haufschild
PNPatricia Niekler
Patricia Niekler
JSJohanna Sack
Johanna Sack
BWBenedikt Weissbrich
Benedikt Weissbrich
KKKerstin Knies
Kerstin Knies
CKChrista Kitz
Christa Kitz
Background: Following the easing of preventive, non-pharmaceutical COVID-19 interventions (NPIs) during the late phase of the pandemic, acute respiratory infections (ARI) in children reemerged. We investigated the viral etiology, seasonality and clinical characteristics of children with ARI treated in primary care practices during this period. Methods: We conducted a prospective, observational study on children ≤ 14 years of age, presenting with acute upper (URTI) or lower (LRTI) ARI in five pediatric primary care practices in Wuerzburg, Germany, from 10/2021 to 05/2022. A maximum of eight children per practice were included on one predefined day per week. Oropharyngeal swabs were analyzed using (multiplex) PCR for 18 viral pathogens. Results: A total of 521 children (median age 3.3 years; IQR 1.6–5.5; 52% male) with ARI were enrolled (28% LRTI). At least one virus was detected in 85%, with human rhinovirus (HRV) (30%), Respiratory Syncytial Virus (RSV) (22%), and SARS-CoV-2 (16%) being the most frequent viruses. Co-detection (≥ 2 viruses) occurred in 156 (30%) patients, were most frequent in children < 2 years of age (38% of 164), and their rate decreased with increasing age ( p = 0.012). Bocavirus (88% of 56), adenovirus (80% of 48) and endemic coronaviruses (70% of 42) showed the highest proportion of co-detection. RSV and human metapneumovirus (hMPV) were predominant in LRTI, whereas HRV and SARS-CoV-2 were more prevalent in URTI. The LRTI rate was 32% of 288 mono-detections and 23% of 156 co-detection. Conclusions: During fall/winter 2021/2022, viral co-detection were common, possibly as a consequence of easing COVID-19-related NPIs, but were not associated with more severe clinical characteristics.

1 January 2026
Verified
Book Chapter
Closed access
PDF file
MKMarkus Knuf
Markus Knuf
FBFolke Brinkmann
Folke Brinkmann
GEGeraldine Engels
Geraldine Engels
JFJohannes Forster
Johannes Forster
UHUlrich Heininger
Ulrich Heininger
WHWalter H. Haas
Walter H. Haas